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ympathectomy Protects Denervated Skin from
raft-Versus-Host Disease
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TDisparity in human leukocyte antigens (HLAs)
etween donors and recipients of hematopoietic cell
ransplantations is the most powerful determinant of
he severity and kinetics of graft-versus-host disease
GVHD) [1]. Other factors, including hematopoietic
ell source (peripheral blood cells vs bone marrow),
onor parity, sex mismatch, and the intensity of the
ransplantation conditioning regimen, also may inﬂu-
nce the development of GVHD [2,3].
The human nervous system has long been thought
o interact with the immune system. However, a direct
linical association between the autonomic nervous
ystem (ANS) and GVHD has not been described.
We observed failure to develop skin GVHD in
enervated dermatomes resulting from a sympathec-
omy in a 61-year-old man with myelodysplastic syn-
rome (refractory cytopenia with multilineage dyspla-
ia) and monosomy 7 (intermediate-2 stage by the
nternational Prognostic Scoring System [4]) who re-
eived a peripheral blood progenitor transplant from a
ex-matched, 10/10 HLA-matched (HLA-A, -B, -C,
DRB1, and -DQB1) unrelated donor, after a prepar-
tive regimen of intravenous ﬂudarabine and targeted
oses of intravenous busulfan. Posttransplantation im-
unosuppression comprised tacrolimus and metho-
rexate. The patient’s past medical history was notable
or a right thoracic sympathectomy during childhood
o treat vascular insufﬁciency. As a consequence, he
ad developed right-sided upper extremity muscle at-
ophy and hemianhidrosis before transplantation.
The posttransplantation course was complicated
y biopsy-proven grade II GVHD involving the skin
nd gastrointestinal tract beginning at day 27,
rompting initiation of systemic therapy with pred-
isone. The rash involved approximately 50% of his
ody surface area, but spared the T5-6 and T9-10
ermatomes (Figures 1 and 2) on the right side.
Recent experimental evidence suggests that such
nteractions between the autonomic nervous system
nd immune system are fundamental to the preserva-
ion of immune homeostasis [5,6]. Both the sympa-
hetic and parasympathetic ANS modulate cytokine
elease from T cells. Sanders et al. [7] showed that
ctivation of the beta-2 adrenergic receptors (ARs) on Ih1 cells can selectively inhibit interferon (INF)-
ecretion and subsequent IgG2a production. Similarly,
oza et al. [8] demonstrated that type 2 interleukin
IL)-13–producing CD4 or CD8 T cells in human
lood respond directly to beta-2 agonists with activa-
ion of protein kinase A activity and inhibition of
-cell receptor–stimulated IL-13, IFN-, and IL-2
ecretion. Conversely, stimulation of the vagus nerve
an decrease local production of tumor necrosis factor
TNF)- through acetylcholine [5]. Clinical and pre-
linical data indicate that TNF- is an important
ediator of acute GVHD, and treatment of acute
VHD by TNF- blockade with etanercept in con-
ert with methylprednisolone produces high complete
esponse rates [1,9]. Furthermore, dendritic cells
DCs) play a critical role in activating immune re-
ponses, and after T-cell–replete hematopoietic cell
ransplantation from allogeneic donors, either host or
onor DCs are capable of initiating GVHD [10-12].
igure 1. Arrows represent skin areas corresponding to T5-6 and
9-10 dermatomes that are spared from acute GVHD (back).n addition, DCs express alpha-1 or beta-2 ARs that
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Letter to the Editor370ediate stimulatory or inhibitory effects on DC mi-
ration and Th1 priming, respectively. For instance,
timulation of beta-2 ARs expressed on skin and bone
arrow–derived DCs decreases IL-12 and increases
L-10, leading to reduced Th1 priming [10].
In the present case, we postulate that the patient’s
revious sympathectomy prevented T-cell stimulation
y beta-2 ARs in the denervated dermatomes, result-
ng in unopposed “dominance” of the parasympathetic
ystem, leading to a local decrease in TNF- and
ther proinﬂammatory cytokines, and locally sparing
kin from GVHD. The precise contribution(s) of DCs
r other T-cell subsets in preventing GVHD in the
etting of sympathectomy is not entirely clear. Our
linical observations suggest an immunoregulatory
ole for the ANS in the pathogenesis of GVHD.
odulation of autonomic pathways may represent
ovel therapeutic strategies for GVHD.
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